Europe — EMA
Orgovyx (Relugolix)
Relugolix, the active ingredient in Orgovyx, is a gonadotropin-releasing hormone (GnRH) antagonist presented as a tablet for oral use. It is indicated for the treatment of advanced prostate cancer in men.
Request sourcing
What is Relugolix?
Relugolix, the active ingredient in Orgovyx, is a gonadotropin-releasing hormone (GnRH) antagonist presented as a tablet for oral use. It is indicated for the treatment of advanced prostate cancer in men. GNH USA supplies Orgovyx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.
GNH USA supplies Orgovyx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.
What is Relugolix used for?
Orgovyx is a GnRH antagonist that acts on the hormonal pathway driving prostate cancer growth.
- Advanced prostate cancer: Improves overall survival and delays disease progression. - Metastatic castration‑resistant prostate cancer: Used in combination with androgen‑deprivation therapy to enhance treatment response. - Hormone‑sensitive prostate cancer: Provides testosterone suppression as part of first‑line therapy.
What are the side effects of Relugolix?
Relugolix may cause a range of adverse reactions, most of which are mild to moderate in intensity.
Common Side Effects: - Hot flashes - Fatigue - Decreased libido - Headache - Nausea - Diarrhoea
Serious or Rare Side Effects: - Cardiovascular events such as myocardial infarction or stroke - Severe allergic reactions (anaphylaxis) - Liver enzyme elevations - Bone fractures - Seizures - Severe hypertension
What precautions apply to Relugolix?
Before using Orgovyx, clinicians should evaluate patient history and monitor for specific risks.
- Cardiovascular assessment: Review history of heart disease, stroke, or thromboembolic events. - Liver function: Check baseline hepatic enzymes and monitor periodically. - Bone health: Assess risk of osteoporosis and consider supplementation. - Drug interactions: Review concomitant medications for potential CYP3A4 interactions. - Pregnancy and lactation: Not indicated for women; avoid exposure. - Store at room temperature: keep the tablet in the original pack and protect from moisture.
What does Relugolix interact with?
Relief
---
"""" """"" " " """" " " "" "" "" """ "" " "" """ ": "" """"""""""""""""""""""""
"" "" """ " "" " """"""" """ "" ""
